Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,499 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Protein Control Clear all
Completed Phase 2 Interventional

Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

NCT06634030
View directory record Official record
Conditions
Wound Healing, Surgical Wound
Interventions
RhPDGF-BB, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 28, 2026, 9:30 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

NCT02112045
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Granix, High dose melphalan (HDR), Autologous Stem Cell Transplant (ASCT)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 28, 2026, 9:30 AM EDT
Terminated Not applicable Interventional

To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease

NCT02649075
View directory record Official record
Conditions
Crohn's Disease
Interventions
Serum-derived Bovine Immunoglobulin / Protein Isolate, Placebo
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
North Little Rock, Arkansas • Hollywood, Florida • Winter Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Not applicable Interventional Results available

Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT01143766
View directory record Official record
Conditions
Conscious Sedation
Interventions
Gabapentin, Standard sedation regimen
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Early Phase 1 Interventional Results available

Pregabalin in the Treatment of Essential Tremor

NCT00646451
View directory record Official record
Conditions
Essential Tremor
Interventions
pregabalin (Lyrica), placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 28, 2026, 9:30 AM EDT
Recruiting Phase 4 Interventional

SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors

NCT04647227
View directory record Official record
Conditions
Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions
coagulation factor VIIa [recombinant]-jncw
Drug
Lead sponsor
American Thrombosis and Hemostasis Network
Network
Eligibility
12 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
21
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 3 Interventional

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

NCT01336751
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vancomycin Dose Optimization in Obesity

NCT06601257
View directory record Official record
Conditions
Pharmacokinetics and Pharmacodynamics
Interventions
Vancomycin (IV)
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

NCT00069095
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
49
States / cities
Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 28, 2026, 9:30 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN)

NCT02975986
View directory record Official record
Conditions
Uric Acid Nephrolithiasis
Interventions
123I-BMIPP, 99mTc-MAG3
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 2 Interventional Results available

The Role of Vasopressin in the Social Deficits of Autism

NCT01962870
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Vasopressin, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Years to 12 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 28, 2026, 9:30 AM EDT
Terminated Phase 3 Interventional

Comparison of Insulin Alone to Insulin With Metformin to Treat Gestational Diabetes Mellitus

NCT03651531
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Insulin, Metformin
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

NCT01845831
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 28, 2026, 9:30 AM EDT
Terminated Phase 2 Interventional Results available

Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies

NCT05846659
View directory record Official record
Conditions
Oligoprogressive
Interventions
IMSA101, Immune checkpoint inhibitor, PULSAR
Drug · Radiation
Lead sponsor
ImmuneSensor Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Protein Weight Loss for Seniors

NCT02730988
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Weight Stable Group
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years to 79 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 28, 2026, 9:30 AM EDT
Terminated Phase 2 Interventional Results available

Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome

NCT01127503
View directory record Official record
Conditions
Velo-cardio-facial Syndrome, Psychosis
Interventions
Metyrosine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
16 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

NCT04843761
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 28, 2026, 9:30 AM EDT
Withdrawn Phase 4 Interventional

Regression of Fatty Heart by Valsartan Therapy

NCT00745953
View directory record Official record
Conditions
Metabolic Syndrome, Lipotoxicity
Interventions
Valsartan, Hydrochlorothiazide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

NCT03921541
View directory record Official record
Conditions
Arginase I Deficiency, Hyperargininemia
Interventions
Pegzilarginase, Placebo
Drug
Lead sponsor
Immedica Pharma AB
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
17
States / cities
Rogers, Arkansas • Orange, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 28, 2026, 9:30 AM EDT
Terminated Not applicable Interventional Results available

Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury

NCT00900666
View directory record Official record
Conditions
Stiff Knee Gait, Brain Injuries
Interventions
placebo, botulinum toxin A (BTX-A)
Drug
Lead sponsor
Mary Free Bed Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of H1N1 Vaccine

NCT01177202
View directory record Official record
Conditions
H1N1 Flu
Interventions
HAC1 Vaccine
Biological
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2016 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Not applicable Interventional

PTSD Mobile App for Cancer Survivors

NCT04058795
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Cancer
Interventions
Cancer Distress Coach (CaDC) App, CaDC + mCoaching, mCBT
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
New York, New York • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 28, 2026, 9:30 AM EDT
Completed Phase 3 Interventional Results available

Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery

NCT01361594
View directory record Official record
Conditions
Diabetes
Interventions
Regular insulin (intensive treatment), Regular Insulin (conventional treatment)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 31, 2014 · Synced Oct 28, 2026, 9:30 AM EDT
Terminated Phase 4 Interventional Results available

Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

NCT03277183
View directory record Official record
Conditions
Anemia, CKD, Atherosclerosis, Cardiovascular
Interventions
Low dose erythropoietin, High dose erythropoietin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 28, 2026, 9:30 AM EDT